TAIAN CITY, China, July 16 China BiologicProducts, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"),one of the leading plasma-based pharmaceutical companies in the People'sRepublic of China ("PRC"), today announced that the Company hosted a forum ofindustry experts on July 10 - 11, 2009, at its headquarters in Tai'an,Shandong Province, to discuss future development strategies for the Company.
Experts from the bio-pharmaceutical industry included Mr. Zhongwei Zheng,head of the research and development center at the Institute of BloodTransfusion at the Chinese Academy of Medical Science, and Mr. Fengshan Wang,Dean of School of Pharmaceutical Sciences at the Shandong University. Messrs.Zheng and Wang and other domestic and international academics and experts,gathered together to discuss strategies for the development of the new ChinaBiologic, which recently became the largest non-state-owned plasma-basedpharmaceutical Company in China following the Company's acquisitions of DalinBiologic Technologies and also its equity investment in Xi'an Huitian BloodProducts.
The forum provided a platform for industry experts to discuss and provideadvice to the Company that could create synergies among its subsidiariesincluding, the initiation of research and development of new drugs, efficientuse of resources among the subsidiaries, quality control procedures duringcollection, production and distribution processes, and other expert opinionsto create long term, sustainable growth for the Company.
"The forum has provided us with many strategic ideas to further the growthof the new China Biologic," said Mr. Chao Ming Zhao, CEO of China BiologicProducts. "We look forward to implementing some of those strategies and createsynergies among our subsidiaries."
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirectmajority-owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. andChongqing Dalin Biologic Technologies Co., Ltd, and its equity investment inXi'an Huitian Blood Products Co., Ltd., is currently the largestnon-state-owned plasma-based biopharmaceutical company approved by the Chinesegovernment. The Company is a fully integrated biologic products company withplasma collection, production and manufacturing, research and development, andcommercial operations. The Company's blood products are irreplaceable duringmedical emergencies, and are used for the prevention and treatment of variousdiseases. It sells its plasma-based biopharmaceutical products to hospitalsand other healthcare facilities in China.
Safe Harbor Statement
This release may contain certain "forward-looking statements" relating tothe business of China Biologic Products, Inc. and its subsidiary companies.All statements, other than statements of historical fact included herein are"forward-looking statements," including statements regarding: the impact ofthe Company's forum for strategy and development on the business andoperations of the Company, including the ability of the Company to createsynergies among its subsidiaries; the ability of the Company to achieve itscommercial objectives; the business strategy, plans and objectives of theCompany and its subsidiaries; and any other statements of non-historicalinformation. These forward-looking statements are often identified by the useof forward-looking terminology such as "believes," "expects" or similarexpressions, involve known and unknown risks and uncertainties. Although theCompany believes that the expectations reflected in these forward-lookingstatements are reasonable, they do involve assumptions, risks anduncertainties, and these expectations may prove to be incorrect. Investorsshould not place undue reliance on these forward-looking statements, whichspeak only as of the date of this press release. The Company's actual resultscould differ materially from those anticipated in these forward-lookingstatements as a result of a variety of factors, including those discussed inthe Company's periodic reports that are filed with the Securities and ExchangeCommission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalfare expressly qualified in their entirety by these factors. Other than asrequired under the securities laws, the Company does not assume a duty toupdate these forward-looking statements.For more information, please contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email: [email protected]
Web: http://www.chinabiologic.com Investor Relations Contact: Mr. Crocker Coulson, President CCG Investor Relations Tel: +1-646-213-1915 (NY office) or Mr. Gary Chin Tel: +1-646-213-1909 Email: [email protected]
SOURCE China Biologic Products, Inc.